The firm has agreed to sell the company to Par Pharmaceutical Companies, which is backed by TPG Capital, for $490m, according to a document filed with US securities regulators.
Warburg acquired JHP for $195m in 2012 from Morgan Stanley Principal Investments. The firm received dividends of around $100m from JHP prior to the sale and will make a return of three times on its investments, said Dow Jones.
Warburg is still interested in the US sterile injectable drug market, which is estimated to be worth $30bn, said the report, citing a source.
TPG bought Par in a take-private deal with an equity value of $1.9bn in july 2011.
The companydevelops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.
Copyright © 2014 AltAssets